ES2836137T3 - Composiciones y métodos útiles para el tratamiento de trastornos del espectro de neuromielitis óptica - Google Patents

Composiciones y métodos útiles para el tratamiento de trastornos del espectro de neuromielitis óptica Download PDF

Info

Publication number
ES2836137T3
ES2836137T3 ES14802790T ES14802790T ES2836137T3 ES 2836137 T3 ES2836137 T3 ES 2836137T3 ES 14802790 T ES14802790 T ES 14802790T ES 14802790 T ES14802790 T ES 14802790T ES 2836137 T3 ES2836137 T3 ES 2836137T3
Authority
ES
Spain
Prior art keywords
inh
nmo
treatment
composition
optic neuritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14802790T
Other languages
English (en)
Spanish (es)
Inventor
Colin Broom
Jeffrey Dayno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2836137T3 publication Critical patent/ES2836137T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES14802790T 2013-11-13 2014-11-12 Composiciones y métodos útiles para el tratamiento de trastornos del espectro de neuromielitis óptica Active ES2836137T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361903643P 2013-11-13 2013-11-13
PCT/US2014/065180 WO2015073514A1 (en) 2013-11-13 2014-11-12 Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders

Publications (1)

Publication Number Publication Date
ES2836137T3 true ES2836137T3 (es) 2021-06-24

Family

ID=51952046

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14802790T Active ES2836137T3 (es) 2013-11-13 2014-11-12 Composiciones y métodos útiles para el tratamiento de trastornos del espectro de neuromielitis óptica

Country Status (7)

Country Link
US (3) US10272142B2 (https=)
EP (1) EP3068424B1 (https=)
JP (3) JP6928809B2 (https=)
BR (1) BR112016010837A8 (https=)
CA (1) CA2930544A1 (https=)
ES (1) ES2836137T3 (https=)
WO (1) WO2015073514A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272142B2 (en) 2013-11-13 2019-04-30 Shire Viropharma Incorporated Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders
JPWO2023100985A1 (https=) 2021-12-03 2023-06-08

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987000360A1 (fr) 1985-06-29 1987-01-15 Hartmut Griepentrog Machine comportant un rotor a paliers magnetiques et une machine electrique a champ radial
WO2001055390A1 (en) * 2000-01-28 2001-08-02 Human Genome Sciences, Inc. Human serpin polynucleotides, polypeptides, and antibodies
ITMI20111390A1 (it) 2011-07-26 2011-10-25 Trivi S R L Gruppo regolabile per la formazione di impasti alimentari
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
EP2825989A4 (en) 2012-03-16 2016-01-06 Alexion Pharma Inc METHODS OF DISPENSING MEDICATION INHIBITING COMPLEMENT TO PATIENTS RECEIVING COMPLEMENT INHIBITOR
CA2916399C (en) * 2013-06-28 2022-08-02 Marc Nolte Combination therapy using a factor xii inhibitor and a c1-inhibitor
US10272142B2 (en) 2013-11-13 2019-04-30 Shire Viropharma Incorporated Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders

Also Published As

Publication number Publication date
EP3068424A1 (en) 2016-09-21
US20150132296A1 (en) 2015-05-14
JP6928809B2 (ja) 2021-09-01
JP2016540746A (ja) 2016-12-28
US20210236607A1 (en) 2021-08-05
EP3068424B1 (en) 2020-09-09
US20190262440A1 (en) 2019-08-29
US11938174B2 (en) 2024-03-26
JP2022125248A (ja) 2022-08-26
US10786557B2 (en) 2020-09-29
JP2020002180A (ja) 2020-01-09
CA2930544A1 (en) 2015-05-21
US10272142B2 (en) 2019-04-30
WO2015073514A1 (en) 2015-05-21
BR112016010837A8 (pt) 2020-04-22

Similar Documents

Publication Publication Date Title
ES2965283T3 (es) Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento
US20130288980A1 (en) Targeting senescent and cancer cells for selective killing by interference with foxo4
CN103635187B (zh) 用于抑制化疗引起的副作用的药物治疗以及相关药物组合物、诊断试剂、筛选技术和试剂盒
US20130288981A1 (en) Targeting senescent cells and cancer cells by interference with jnk and/or foxo4
ES2655291T3 (es) Uso de cladribina para tratar neuromielitis óptica
JP2022125248A (ja) 視神経脊髄炎スペクトル障害の治療に有用な組成物及び方法
CN112423752A (zh) C5a拮抗剂和ANCA相关性血管炎的剂量和疗效
CN115605191A (zh) 用于治疗脑癌或cns癌症的羟基脲甲基-酰基富烯
CA2962406A1 (en) Treatment of rett syndrome
Kusunoki et al. Tacrolimus therapy for systemic lupus erythematosus without renal involvement: a preliminary retrospective study
US20230067811A1 (en) Modulating lymphatic vessels in neurological disease
Moore et al. Inhibitor of apoptosis protein (IAP) profiling in experimental autoimmune encephalomyelitis (EAE) implicates increased XIAP in T lymphocytes
JP2023525296A (ja) 膵臓がんを治療するための方法
Guerguinova et al. Membranous glomerulonephritis–gender-related differences of disease course and evaluation of therapy efficiency
Légaré et al. New Horizons in Myotonic Dystrophy Type 1: Cellular Senescence as a Therapeutic Target
US20190062452A1 (en) Methods and Compositions for the Treatment of Immunomodulatory Diseases and Disorders
RU2835509C2 (ru) Дозирование и эффект c5a антагониста при anca-ассоциированном васкулите
JP4437385B2 (ja) アポトーシス増強剤
US11345747B2 (en) Methods and compositions for the treatment of diseases and disorders
CN119136808A (zh) 药物组合物及其应用
CA2992145C (en) Methods and compositions for the treatment of immunomodulatory diseases and disorders
ES2948443T3 (es) Modulación de la ciliogénesis